Physician profile
Abbas Omais
NPI 1699748046
$14,862.46
in general payments reported to CMS, 2019-2025
38 companies · $2,208 in 2025
The $2,208 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,520 · 2020: $1,142 · 2021: $1,887 · 2022: $2,005 · 2023: $2,689 · 2024: $2,411 · 2025: $2,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,019 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,019.44 |
| Education | $289.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,894.61 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,449.65 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $958.52 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $803.08 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Mallinckrodt Hospital Products INC. | $719.93 | 2020-2025 | Acthar |
| Grifols USA, LLC | $709.98 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $705.38 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $571.74 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $459.84 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $449.87 | 2021-2025 | Glassia, Cuvitru |
| Harmony Biosciences LLC | $435.11 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $391.97 | 2019-2024 | Xywav |
| United Therapeutics Corporation | $377.66 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Insmed, INC. | $368.47 | 2019-2025 | Arikayce, Brinsupri |
| Amgen INC. | $252.29 | 2022-2025 | Tezspire |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $246.02 | 2022-2024 | Purified Cortrophin Gel |
| Sunovion Pharmaceuticals INC. | $239.39 | 2019-2021 | |
| Baxter Healthcare | $222.18 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Philips North America LLC | $178.74 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $175.95 | 2019 | |
| Merck Sharp & Dohme LLC | $164.88 | 2020-2023 | Belsomra |
| Electromed, INC. | $149.04 | 2022-2024 | Smartvest |
| Genentech USA, INC. | $129.65 | 2019-2022 | |
| Axsome Therapeutics, INC. | $103.84 | 2023-2025 | Sunosi |
| Verona Pharma, INC. | $96.89 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $94.40 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $92.99 | 2025 | |
| Vifor Pharma, INC. | $74.82 | 2024-2025 | Zemaira, Veltassa |
| Shire North American Group INC | $64.63 | 2019 | |
| Pfizer INC. | $60.92 | 2019-2024 | |
| Viatris Specialty LLC | $58.76 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $46.00 | 2021-2022 | |
| Resmed Corp | $36.25 | 2019-2024 | |
| Nabriva Therapeutics, Plc | $18.34 | 2021 | |
| Pulmonx Corporation | $16.67 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Avadel Cns Pharmaceuticals, LLC | $15.54 | 2024 | Lumryz |
| W. L. Gore & Associates, INC. | $14.81 | 2025 | Gore Synecor Biomaterial |
| Inogen, INC. | $13.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbas Omais listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.